Tempest Therapeutics presented new clinical data on its dual-targeting CAR-T therapy candidate TPST-2003 at the ISCT 2026 meeting. The therapy targets CD19 and BCMA antigens and showed promising results in the REDEEM-1 Phase 1/2a trial for patients with relapsed/refractory multiple myeloma, including those with extramedullary disease. Earlier data showed a 100% complete response rate in six evaluable patients, indicating strong potential for improved treatment outcomes. Tempest plans to continue trials and aims to position TPST-2003 as a leading therapy for this condition.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
UnitedHealth Group reported second-quarter earnings that surpassed expectations, driven by better management of high medical costs and AI investments to streamline operations. The company raised its 2026 adjusted earnings forecast to $19.50-$20 per s...
Meta Platforms has been upgraded to a buy rating due to its new cloud business, which is expected to stabilize cash flow and improve profitability. Despite heavy capital expenditures, Meta maintains strong free cash flow margins and operational effic...
Bitcoin Treasury Capital, a Stockholm-based firm, has received approval to issue 195,078 Class A preferred shares on the Spotlight Stock Market, starting July 20, 2026. These shares, priced at SEK 120 each, offer a 10% annual dividend backed entirely...
Bitcoin price recently hit a strong resistance level at $65,600 but failed to break through, signaling a possible reversal. Short-term momentum is weakening, suggesting the price may decline unless a sudden surge occurs. Key support levels include th...
